J 
Jilin Province Huinan Changlong Bio-pharmacy Co 8049.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
2.70
+1.89%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.05bn
FY2016FY2025
Net income
CN¥232.0m
FY2016FY2025
Free cash flow
CN¥350.9m
FY2016FY2025
Shareholders' equity
CN¥1.97bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.05bn | CN¥1.03bn | CN¥981.7m | CN¥981.7m | CN¥822.9m | CN¥725.9m | CN¥753.4m | CN¥755.5m | CN¥752.7m | CN¥763.0m |
| Gross profit | CN¥883.8m | CN¥799.3m | CN¥681.3m | CN¥755.9m | CN¥676.6m | CN¥619.1m | CN¥628.0m | CN¥620.7m | CN¥619.5m | CN¥605.2m |
| Research and development | — | — | CN¥15.3m | CN¥22.2m | CN¥24.0m | CN¥38.7m | CN¥13.6m | CN¥389,613 | CN¥1.7m | CN¥324,289 |
| Operating income | CN¥250.3m | CN¥244.0m | CN¥231.9m | CN¥230.8m | CN¥207.2m | CN¥175.9m | CN¥204.6m | CN¥217.4m | CN¥201.5m | CN¥195.3m |
| Net income | CN¥232.0m | CN¥214.9m | CN¥172.9m | CN¥225.8m | CN¥167.1m | CN¥147.6m | CN¥168.8m | CN¥188.1m | CN¥168.4m | CN¥166.4m |
| Diluted earnings per share | 0.41 | 0.38 | 0.31 | 0.40 | 0.30 | 0.26 | 0.30 | 0.34 | 0.30 | 0.30 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥3.12bn | CN¥2.95bn | CN¥2.70bn | CN¥2.77bn | CN¥2.42bn | CN¥2.10bn | CN¥1.95bn | CN¥1.81bn | CN¥1.44bn | CN¥1.25bn |
| Cash and short-term investments | CN¥794.9m | CN¥628.8m | CN¥764.8m | CN¥1.20bn | CN¥305.9m | CN¥330.8m | CN¥957.6m | CN¥851.5m | CN¥692.2m | CN¥534.6m |
| Total liabilities | CN¥1.15bn | CN¥1.05bn | CN¥978.0m | CN¥887.2m | CN¥721.6m | CN¥535.5m | CN¥505.0m | CN¥492.1m | CN¥264.8m | CN¥243.4m |
| Debt | CN¥6.4m | CN¥89.0m | CN¥97.1m | CN¥2.8m | CN¥400,000 | CN¥400,000 | CN¥2.4m | CN¥2.4m | CN¥3.0m | CN¥3.0m |
| Shareholders' equity | CN¥1.97bn | CN¥1.90bn | CN¥1.73bn | CN¥1.88bn | CN¥1.70bn | CN¥1.57bn | CN¥1.44bn | CN¥1.32bn | CN¥1.18bn | CN¥1.01bn |
| Shares outstanding | 560m | 560m | 560m | 560m | 560m | 560m | 560m | 560m | 560m | 560m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥365.4m | CN¥256.2m | CN¥368.6m | CN¥238.0m | CN¥250.9m | CN¥176.4m | CN¥154.6m | CN¥161.9m | CN¥170.9m | CN¥144.4m |
| Capital spending | −CN¥14.5m | −CN¥12.9m | −CN¥37.1m | −CN¥13.2m | −CN¥108.3m | −CN¥115.2m | −CN¥47.7m | −CN¥39.3m | −CN¥41.7m | −CN¥22.2m |
| Free cash flow | CN¥350.9m | CN¥243.4m | CN¥331.4m | CN¥224.8m | CN¥142.6m | CN¥61.2m | CN¥106.8m | CN¥122.6m | CN¥129.2m | CN¥122.2m |
| Dividends paid | −CN¥138.3m | −CN¥40.8m | −CN¥330.9m | −CN¥32.9m | −CN¥30.7m | −CN¥18.5m | −CN¥33.6m | −CN¥36.6m | −CN¥24,497 | −CN¥38,495 |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥500.5m | CN¥253.7m | CN¥270.0m | CN¥270.0m | CN¥256.0m | CN¥256.0m | CN¥284.7m | CN¥284.7m |
| Gross profit | CN¥420.2m | CN¥213.0m | CN¥231.0m | CN¥231.0m | CN¥210.9m | CN¥210.9m | CN¥215.9m | CN¥215.9m |
| Operating income | CN¥143.7m | CN¥88.5m | CN¥82.8m | CN¥82.8m | CN¥72.2m | CN¥72.2m | CN¥47.5m | CN¥47.5m |
| Net income | CN¥141.3m | CN¥71.6m | CN¥55.9m | CN¥55.9m | CN¥60.1m | CN¥60.1m | CN¥46.6m | CN¥46.6m |
| Diluted earnings per share | 0.25 | 0.13 | 0.10 | 0.10 | 0.11 | 0.11 | 0.08 | 0.08 |
| Total assets | CN¥3.19bn | CN¥3.19bn | CN¥3.12bn | CN¥3.12bn | CN¥3.09bn | CN¥3.09bn | CN¥2.95bn | CN¥2.95bn |
| Cash and short-term investments | CN¥1.05bn | CN¥1.05bn | CN¥794.9m | CN¥802.9m | CN¥872.9m | CN¥872.9m | CN¥628.8m | CN¥680.8m |
| Debt | CN¥466,516 | CN¥466,602 | CN¥6.4m | CN¥466,602 | CN¥89.0m | CN¥84.5m | CN¥89.0m | CN¥84.5m |
| Shareholders' equity | CN¥2.11bn | CN¥2.11bn | CN¥1.97bn | CN¥1.97bn | CN¥2.02bn | CN¥2.02bn | CN¥1.90bn | CN¥1.90bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 2.3% | 7.7% | 5.3% |
| Operating income | 2.8% | 7.3% | 4.5% |
| Net income | 0.9% | 9.5% | 5.4% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 80.9% | 77.2% | 79.0% | 80.0% |
| Operating margin | 23.8% | 23.7% | 24.0% | 25.1% |
| Net margin | 21.5% | 20.9% | 20.8% | 21.5% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 4.7 | 3.4 | 4.8 | 2.0 | 3.6 | 4.6 | 3.0 | 2.9 | 5.3 | 5.5 |
| Price to sales | 1.0 | 0.7 | 0.8 | 0.5 | 0.7 | 0.9 | 0.7 | 0.7 | 1.2 | 1.2 |
Dividends and splits
Per share, in the currency the company pays
Paid for 8 years. Last went ex-dividend on 24 Jun 2025.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.273 | 0.069 | 0.553 | 0.063 | 0.063 | 0.035 | 0.07 | 0.07 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.